TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 39395231
Drug: FAP-IL2v 10
Normalized name: AVA-6000 (FAP-activated doxorubicin prodrug)
Approvals — FDA: no, EMA: no, PMDA: no
Description: FAP-IL2v 10 mg administered once every 3 weeks (Q3W) or once weekly (QW) for 4 weeks then once every 2 weeks (Q2W) with corresponding atezolizumab regimens.
Study: 39395266
Drug: Fruquintinib monotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fruquintinib monotherapy
Study: 39395266
Drug: Fruquintinib combined
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fruquintinib combined with chemotherapy and/or anti-PD-1 antibodies
Study: 39395411
Drug: Anti-PD-1 plus
Normalized name: Anti-PD-1 monoclonal antibody MGA012
DrugBank: Retifanlimab (DB15766)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anti-PD-1 plus chemotherapy (combo)
Study: 39395424
Drug: Standard-of-care (oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard-of-care (oral PrEP and PEP)
Study: 39395655
Drug: Garetosmab (anti-activin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Garetosmab (anti-activin A antibody)
Study: 39395753
Drug: Standard-dose inactivated
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard-dose inactivated influenza vaccine (IIV4)
Study: 39395964
Drug: Conventional dosage
Normalized name: osage orange pollen extract
DrugBank: Maclura pomifera pollen (DB10988)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional dosage reduction
Study: 39396529
Drug: Denifanstat 50
Normalized name: Denifanstat
DrugBank: Denifanstat (DB17576)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Denifanstat 50 mg once per day for 52 weeks
Study: 39396702
Drug: High-dose DHA
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose DHA supplementation
Study: 39396760
Drug: Low-protein control
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-protein control meal (5 g protein)
Study: 39396987
Drug: Celiac plexus
Normalized name: Bos taurus solar plexus preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Celiac plexus block (anesthetic and steroid combination injected into the celiac plexus)
Study: 39396991
Drug: Internet-delivered Cognitive
Normalized name: DELIVER
Approvals — FDA: no, EMA: no, PMDA: no
Description: Internet-delivered Cognitive Behavioral Therapy (iCBT) with planned feedback
Study: 39396991
Drug: Internet-delivered Cognitive
Normalized name: DELIVER
Approvals — FDA: no, EMA: no, PMDA: no
Description: Internet-delivered Cognitive Behavioral Therapy (iCBT) with on-demand feedback
Study: 39397156
Drug: Cumulative intake
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cumulative intake >150 ml/kg MOM ± DHM within 7-10 days PNA
Study: 39397784
Drug: Prime-2-CoV_Beta vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prime-2-CoV_Beta vaccine (orf virus-based multi-antigen COVID-19 vaccine)
Study: 39398317
Drug: Anti-IgE therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anti-IgE therapy (omalizumab)
Study: 39398317
Drug: Anti-IL-5/5R therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anti-IL-5/5R therapy
Study: 39398317
Drug: Anti-IL-4R therapy
Normalized name: tetracycline
DrugBank: Tetracycline (DB00759)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Anti-IL-4R therapy
Study: 39399770
Drug: Preoperative subacromial
Normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Preoperative subacromial injection of bupivacaine and epinephrine
Study: 39399770
Drug: Preoperative subacromial
Normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Preoperative subacromial injection of bupivacaine
Study: 39400005
Drug: Comprehensive remote
Approvals — FDA: no, EMA: no, PMDA: no
Description: Comprehensive remote monitoring (RM) including a monthly symptom questionnaire and notifications for biventricular pacing, premature ventricular contraction, atrial arrhythmias
Study: 39400005
Drug: Standard daily
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard daily remote monitoring (control group)
Study: 39400265
Drug: Herbal formulation,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Herbal formulation, details on dosage and duration not available
Study: 39400653
Drug: Aromatherapy group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aromatherapy group (inhaled Lavender essential oil)
Study: 39401332
Drug: Intranasal transplantation
Normalized name: Washed Microbiota Transplantation
DrugBank: Washed Microbiota Transplantation (DB15745)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intranasal transplantation of ProtheraCytes
Study: 39401503
Drug: EP-104IAR (25
Approvals — FDA: no, EMA: no, PMDA: no
Description: EP-104IAR (25 mg intra-articular injection)
Study: 39401504
Drug: Iron supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Iron supplementation (ferrous sulphate 12.5 mg for 6-23 months; 30.0 mg for 24 months and older)
Study: 39402027
Drug: Low dose
Normalized name: Low Dose ASA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low dose peri-operative dexamethasone followed by pre-operative stereotactic radiosurgery (pSRS)
Study: 39402027
Drug: High dose
Normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
Approvals — FDA: no, EMA: no, PMDA: no
Description: High dose peri-operative dexamethasone followed by pre-operative stereotactic radiosurgery (pSRS)
Study: 39402032
Drug: Tebentafusp treatment
Normalized name: Tebentafusp
DrugBank: Tebentafusp (DB15283)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Tebentafusp treatment
Study: 39402448
Drug: IV difelikefalin
Normalized name: difelikefalin
DrugBank: Difelikefalin (DB11938)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: IV difelikefalin (3.0 mcg/kg) in NDD subjects with mild renal impairment
Study: 39402448
Drug: IV difelikefalin
Normalized name: difelikefalin
DrugBank: Difelikefalin (DB11938)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: IV difelikefalin (3.0 mcg/kg) in NDD subjects with moderate or severe renal impairment
Study: 39402448
Drug: IV difelikefalin
Normalized name: difelikefalin
DrugBank: Difelikefalin (DB11938)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: IV difelikefalin (0.5, 1.0, or 2.5 mcg/kg) in ESRD subjects undergoing HD
Study: 39402517
Drug: PE+ therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: PE+ therapy
Study: 39402688
Drug: Patient intervention
Normalized name: patent blue violet
DrugBank: Patent Blue (DB13967)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patient intervention including detection of elevated blood pressure, educational materials, lifestyle modification advice, and medication where needed.
Study: 39403266
Drug: 20% human
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20% human serum albumin solution injected via the artery immediately after successful reperfusion (maximum dose 0.60 g/kg)
Study: 39403266
Drug: Endovascular treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Endovascular treatment alone (ET cohort)
Study: 39403561
Drug: Booster dose
Normalized name: SARS-COV-2 (COVID-19) Vaccine, mRNA (Moderna) 50 MCG/0.5 ML Intramuscular Suspension [MODERNA COVID-19 VACCINE BOOSTER DOSE]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Booster dose of BNT162b2 vaccine
Study: 39403626
Drug: Eftilagimod alpha
Normalized name: alpha tocopherol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Eftilagimod alpha (30 mg subcutaneously every 2 weeks for eight 3-week cycles and then every 3 weeks for up to 54 weeks) plus Pembrolizumab (200 mg intravenously every 3 weeks for up to 105 weeks)
Study: 39403781
Drug: Topical therapy,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical therapy, methotrexate, adalimumab, secukinumab, or guselkumab (effective treatment achieving PASI 90)
Study: 39404994
Drug: Eblasakimab 400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Eblasakimab 400 mg
Study: 39404994
Drug: Eblasakimab 600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Eblasakimab 600 mg
Study: 39405373
Drug: FDA-approved new-generation
Approvals — FDA: no, EMA: no, PMDA: no
Description: FDA-approved new-generation drug-eluting stent followed by 3 or 6 months of DAPT
Study: 39405605
Drug: CIETAI combined
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: CIETAI combined with PD-1 inhibitor tislelizumab plus oxaliplatin, followed by standard concomitant chemoradiotherapy (capecitabine and 50.4 Gy radiation). Intravenous tislelizumab was administered for an additional two cycles.
Study: 39405911
Drug: Doxorubicin (DOX)
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Doxorubicin (DOX) + Metformin (MET)
Study: 39405978
Drug: Spermidine trihydrochloride
Normalized name: spermidine
DrugBank: Spermidine (DB03566)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Spermidine trihydrochloride supplement at 40 mg/day
Study: 39406392
Drug: Postoperative iCav
Normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Postoperative iCav NIVO (1-5-10 mg)
Study: 39406392
Drug: Historical pooled
Normalized name: typhus, historical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Historical pooled cohort of Belgian rHGG patients treated with anti-VEGF therapies
Study: 39406449
Drug: Short term
Normalized name: Short Term Oral Swab System KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Short term intensive insulin therapy (SIIT) followed by linagliptin 5 mg/day for 48 weeks
Study: 39406449
Drug: Short term
Normalized name: Short Term Oral Swab System KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Short term intensive insulin therapy (SIIT) followed by metformin 1000 mg/day for 48 weeks
Study: 39406449
Drug: Short term
Normalized name: Short Term Oral Swab System KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Short term intensive insulin therapy (SIIT) followed by combination linagliptin plus metformin for 48 weeks
Study: 39406449
Drug: Short term
Normalized name: Short Term Oral Swab System KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Short term intensive insulin therapy (SIIT) followed by lifestyle modification alone for 48 weeks (control)
Study: 39407315
Drug: Magnesium sulphate
Normalized name: Magnesium sulphate
DrugBank: Magnesium (DB14513)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Magnesium sulphate (MgSO4) iontophoresis plus conventional physical therapy program
Study: 39407315
Drug: High-power pain-threshold
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-power pain-threshold ultrasound (HPPT-US) plus conventional therapy
Study: 39407325
Drug: mannitol-potentiated low-dose
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: mannitol-potentiated low-dose amikacin
Study: 39407325
Drug: ceftriaxone or
Approvals — FDA: no, EMA: no, PMDA: no
Description: ceftriaxone or amikacin standard dose
Study: 39407334
Drug: Treat-to-target-driven fixed
Normalized name: trimethylsilyl treated diimethiconol-trimethylsiloxysilicate crosspolymer (45-55 WW)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treat-to-target-driven fixed dose retreatment strategy (usual care group) - retreated with fixed rituximab doses (1 × 1000 mg IV) in case of loss of disease control (DAS28-CRP ≥ 3.2)
Study: 39407334
Drug: Fixed interval
Normalized name: Humalog Mix
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fixed interval disease-activity guided dose optimisation strategy (experimental group) - 24-weekly rituximab treatment with tapering doses: 1 × 1000 mg IV (maximal dose), 1 × 500 mg IV, and 1 × 200 mg IV (minimal dose)
Study: 39407334
Drug: Fixed interval
Normalized name: Humalog Mix
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fixed interval disease-activity guided dose optimisation strategy (experimental group)
Study: 39407334
Drug: Treat-to-target-driven fixed
Normalized name: trimethylsilyl treated diimethiconol-trimethylsiloxysilicate crosspolymer (45-55 WW)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treat-to-target-driven fixed dose retreatment strategy (usual care group)
Study: 39407366
Drug: Routine physical
Normalized name: hypochlorite
DrugBank: Hypochlorite (DB11123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Routine physical therapy (control group A)
Study: 39408354
Drug: 2'-Fucosyllactose (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2'-Fucosyllactose (3 g/d)
Study: 39408601
Drug: Taldefgrobep alfa
Normalized name: Taldefgrobep alfa
DrugBank: Talditercept alfa (DB16337)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Taldefgrobep alfa as an adjunct to SMN upregulators
Study: 39410716
Drug: Potassium supplements
Normalized name: POTASSIUM SUPPLEMENTS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Potassium supplements (T3)
Study: 39410716
Drug: Magnesium supplements
Normalized name: Magnesium supplements, alimentary tract and metabolism
Approvals — FDA: no, EMA: no, PMDA: no
Description: Magnesium supplements (T2)
Study: 39410716
Drug: Both magnesium
Normalized name: Bothrops atrox venom
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both magnesium and potassium supplements (T4)
Study: 39411383
Drug: Morphine (0.05
Approvals — FDA: no, EMA: no, PMDA: no
Description: Morphine (0.05 mg/kg; i.v.) + oral pramipexole (0.25 mg)
Study: 39411383
Drug: Morphine (0.1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Morphine (0.1 mg/kg; i.v.) + oral placebo
Study: 39411812
Drug: Pembrolizumab 200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pembrolizumab 200 mg plus carboplatin-paclitaxel (four to six cycles) followed by pembrolizumab 400 mg (six cycles)
Study: 39412509
Drug: Subcutaneous semaglutide
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous semaglutide 2.4 mg
Study: 39412619
Drug: Controlled Administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Controlled Administration Device (CAD)
Study: 39412628
Drug: Triptorelin pamoate
Normalized name: Triptorelin Pamoate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triptorelin pamoate 22.5 mg (day 1 and month 6)
Study: 39412860
Drug: Multidisciplinary home-based
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multidisciplinary home-based rehabilitation program (32 sessions for physical therapy, 8 sessions for occupational therapy, 4 sessions for nutrition, 8 sessions for psychology, and 4 sessions for nursing and podiatry over 4 months)
Study: 39413050
Drug: Super-oxidized solution
Normalized name: Super Spot Remover
Approvals — FDA: no, EMA: no, PMDA: no
Description: Super-oxidized solution
Study: 39413735
Drug: Gemcitabine (1,000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gemcitabine (1,000 mg/m²) plus toripalimab
Study: 39414268
Drug: Treatment as
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment as usual (TAU) provided by regular mental health clinics
Study: 39414276
Drug: Standardised treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standardised treatment including LLN dissection (LLND) after neoadjuvant treatment and TME surgery.
Study: 39414276
Drug: Neoadjuvant treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neoadjuvant treatment by trained radiation oncologists followed by TME surgery.
Study: 39414276
Drug: Standardised treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standardised treatment including LLND.
Study: 39414279
Drug: Proton pump
Normalized name: Proton pump inhibitor
Approvals — FDA: no, EMA: no, PMDA: no
Description: Proton pump inhibitors (PPIs) including omeprazole, esomeprazole, and pantoprazole
Study: 39414294
Drug: High-load strength
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-load strength training (2 weekly sessions for 12 weeks)
Study: 39414341
Drug: Weekly WhatsApp
Normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Weekly WhatsApp messages on healthy behaviours (Control)
Study: 39414418
Drug: Once-weekly efanesoctocog
Approvals — FDA: no, EMA: no, PMDA: no
Description: Once-weekly efanesoctocog alfa prophylaxis 50 IU/kg for 52 weeks (Arm A)
Study: 39414418
Drug: On-demand efanesoctocog
Normalized name: Efanesoctocog alfa
DrugBank: Efanesoctocog alfa (DB16662)
Approvals — FDA: no, EMA: no, PMDA: no
Description: On-demand efanesoctocog alfa 50 IU/kg for 26 weeks followed by 26 weeks once-weekly prophylaxis (50 IU/kg; Arm B)
Study: 39414418
Drug: Pre-study treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pre-study treatment
Study: 39414987
Drug: JNJ-42165279 (25
Approvals — FDA: no, EMA: no, PMDA: no
Description: JNJ-42165279 (25 mg, twice-daily)
Study: 39415283
Drug: 12-week structured
Normalized name: risedronate
DrugBank: Risedronic acid (DB00884)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 12-week structured physical activity programme supervised by a sport medicine physician, preceded by three psychoeducation sessions on healthy eating habits.
Study: 39415344
Drug: Lotiglipron 80
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lotiglipron 80 mg
Study: 39415344
Drug: Lotiglipron 200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lotiglipron 200 mg (five-step titration)
Study: 39415650
Drug: Adjunctive brexpiprazole
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjunctive brexpiprazole (2–3 mg/day)
Study: 39415650
Drug: Adjunctive placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjunctive placebo (brexpiprazole withdrawal)
Study: 39415900
Drug: MP0250 in
Normalized name: Designed ankyrin repeat protein (MP0250)
Approvals — FDA: no, EMA: no, PMDA: no
Description: MP0250 in combination with bortezomib and dexamethasone
Study: 39415923
Drug: Antithrombotic therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antithrombotic therapy (AT-E)
Study: 39415930
Drug: Venetoclax (VEN)
DrugBank: Venetoclax (DB11581)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Venetoclax (VEN) at doses of 400, 600, or 800 mg combined with liposomal vincristine (L-VCR) at 2.25 mg/m weekly
Study: 39415930
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of VEN and L-VCR
Study: 39416174
Drug: ADCT-701, a
Approvals — FDA: no, EMA: no, PMDA: no
Description: ADCT-701, a DLK1 targeting antibody-drug conjugate (ADC)
Study: 39416950
Drug: Mini-dose dexmedetomidine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mini-dose dexmedetomidine (median 0.02 μg/kg/h)
Study: 39416990
Drug: Quadrivalent Recombinant
Normalized name: INFLUENZA VACCINE,QUADRIVALENT RECOMBINANT (PF),SYRINGE,0.5ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Quadrivalent Recombinant Influenza Vaccine (RIV)
Study: 39416990
Drug: Standard-Dose Inactivated
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard-Dose Inactivated Influenza Vaccine (SD IIV)
Study: 39417152
Drug: Daily 2
Normalized name: CVS Oil-Free Daily 2% Acne Wash
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily 2 mg mometasone irrigations for 2 months in an optimized position as determined by a patient-specific 3D printed irrigation model (MG)
Study: 39417152
Drug: Daily 2
Normalized name: CVS Oil-Free Daily 2% Acne Wash
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily 2 mg mometasone irrigations for 2 months with a head tilt of 90° to the side with fluid entering the lower nostril (BG)
Study: 39417152
Drug: Daily 2
Normalized name: CVS Oil-Free Daily 2% Acne Wash
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily 2 mg mometasone irrigations for 2 months with standard head-forward and natural side-tilt position (CG)
Study: 39417218
Drug: Reduced 1+1
Normalized name: Iron, reduced
DrugBank: Iron (DB01592)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Reduced 1+1 PCV dosing schedule
Study: 39418029
Drug: LEN-IE (lenvatinib
Approvals — FDA: no, EMA: no, PMDA: no
Description: LEN-IE (lenvatinib 14 mg/m2 orally once daily + ifosfamide 3000 mg/m2 IV + etoposide 100 mg/m2 IV on days 1-3 of each cycle)
Study: 39418029
Drug: IE (ifosfamide
Approvals — FDA: no, EMA: no, PMDA: no
Description: IE (ifosfamide 3000 mg/m2 IV + etoposide 100 mg/m2 IV on days 1-3 of each cycle)
Study: 39418340
Drug: Socazolimab (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Socazolimab (5 mg/kg) and nab-paclitaxel (260 mg/m2) Q3w
Study: 39418460
Drug: Prolonged exposure
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prolonged exposure (PE) therapy plus sertraline
Study: 39418644
Drug: CPX-351 plus
Normalized name: CPX
DrugBank: DPCPX (DB12946)
Approvals — FDA: no, EMA: no, PMDA: no
Description: CPX-351 plus venetoclax (CPX-351 30 units/m2: daunorubicin 13.2 mg/m2 and cytarabine 30 mg/m2; venetoclax 400 mg)
Study: 39418883
Drug: Lapatinib +
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lapatinib + Trastuzumab (L + T)
Study: 39418883
Drug: Trastuzumab followed
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trastuzumab followed by Lapatinib (T→L)
Study: 39419054
Drug: Induction chemotherapy
Normalized name: human sputum, Bordetella pertussis infected
Approvals — FDA: no, EMA: no, PMDA: no
Description: Induction chemotherapy with chemoradiotherapy
Study: 39419061
Drug: Neoadjuvant treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neoadjuvant treatment with three cycles of intravenous paclitaxel (200 mg/m2) followed by adjuvant treatment.
Study: 39419061
Drug: Neoadjuvant treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neoadjuvant treatment with three cycles of intravenous paclitaxel (200 mg/m2).
Study: 39419061
Drug: Adjuvant treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjuvant treatment following neoadjuvant treatment.
Study: 39419348
Drug: Sugammadex (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sugammadex (2 mg/kg for TOF count ≥1 and 4 mg/kg for TOF count = 0)
Study: 39419615
Drug: Internet-delivered guided
Normalized name: DELIVER
Approvals — FDA: no, EMA: no, PMDA: no
Description: Internet-delivered guided self-help tinnitus treatment based on ACT combined with tailored sound therapy
Study: 39419615
Drug: Tailored sound
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tailored sound therapy alone
Study: 39420338
Drug: BDP/FF/G
Approvals — FDA: no, EMA: no, PMDA: no
Description: BDP/FF/G
Study: 39420468
Drug: Angiotensin receptor-neprilysin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Angiotensin receptor-neprilysin inhibitor (ARNI)
Study: 39420468
Drug: Angiotensin receptor-neprilysin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Angiotensin receptor-neprilysin inhibitor (ARNI) with PDC ≥ 80%
Study: 39421567
Drug: MY-Skills intervention
Approvals — FDA: no, EMA: no, PMDA: no
Description: MY-Skills intervention (yoga and self-management education), offered twice a week for eight weeks, each session lasting two hours.
Study: 39421612
Drug: Cholesfytol NG
Normalized name: NG
DrugBank: Nitroglycerin (DB00727)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cholesfytol NG (1,000 mg Amla fruit and 50 mg Olive fruit standardized extracts)
Study: 39422261
Drug: CV0501 12
Approvals — FDA: no, EMA: no, PMDA: no
Description: CV0501 12 μg dose
Study: 39422261
Drug: CV0501 3
Approvals — FDA: no, EMA: no, PMDA: no
Description: CV0501 3 or 6 μg dose
Study: 39422598
Drug: Fianlimab +
Normalized name: Fianlimab
DrugBank: Fianlimab (DB18858)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fianlimab + cemiplimab (1 to 40 mg/kg of fianlimab plus 350 mg of cemiplimab every 3 weeks)